Cancer cells are dependent on a relatively small number of anti-apoptotic proteins for their survival, including the anti-apoptotic B-cell lymphoma family (BCL-2) proteins, inhibitors of apoptosis proteins (IAPs) and cellular Fas-associated death domain (FADD)-like IL1β (Interleukin-1β)-converting enzyme-inhibitory protein (FLIP), all of which are established anti-cancer therapeutic targets [3]. The gene discussed is IL1B; the disease is cancer.